Cambridge, UK, Remote and RTP,NC
Tel: +44 1223 981750
Biofidelity’s mission is to improve and extend cancer patients’ lives by enabling better targeting of therapies, early detection of treatment resistance, and routine monitoring of treatment response. Our unique technology is designed to allow rapid, broad adoption of our assays in testing labs around the world, enabling a step change in patient care. At Biofidelity we are proud to have built a culture of humanity, openness and high expectations. We work towards well-defined goals, with a strong belief that we can bring real benefits to patients. Our people are keen to take responsibility for their work and share both their successes and challenges.
8 articles with Biofidelity
Biofidelity, a revolutionary genomic technology company dedicated to unleashing the potential of genomics to transform human health and the world we live in, announced the issuance of several new patents in the US, Europe, and China.
Biofidelity, a pioneer in precision cancer diagnostics, has successfully completed a heavily oversubscribed $23 million Series A+ investment round, led by Octopus Ventures and backed by SBI Investment Co. Ltd. and existing investors.
Biofidelity, a pioneer in precision cancer diagnostics, has expanded its Scientific Advisory Board to include Lee N. Newcomer, MD.
Biofidelity, a pioneer in precision cancer diagnostics, praised California Governor Gavin Newsom and the California legislature for the October 6th passage of SB 535, a bill that prohibits health care insurers that already cover biomarker testing from requiring prior authorization for patients with advanced stage cancer.
Successful alpha testing of Biofidelity's ASPYRE-Lung reagents demonstrates breakthrough capabilities and ease of use
Biofidelity Ltd, the cancer diagnostics company, announced the successful completion of alpha testing of its new ASPYRE-Lung reagents at multiple laboratory locations in the US and UK.
There has been a flurry of expansion activity in the life sciences industry as biopharma and diagnostic companies expand manufacturing sites. Here’s a look.
Biofidelity Ltd, the cancer diagnostics company, announces the opening of its US headquarters in Research Triangle Park, North Carolina, expanding its presence in the key US market ahead of its first product launch later this year.
Biofidelity Ltd, the cancer diagnostics company, announces the members of its newly-formed Scientific Advisory Board with the appointments of leaders from the clinical, pharmaceutical and patient advocacy fields.